Breaking News

Provention Bio Completes $35M Equity Investment from Sanofi US

Companies collaborating to expand access to TZIELD, the first approved disease-modifying therapy for type 1 diabetes.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, completed the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement.   “Our Sanofi co-promotion agreement, together with this equity investment, bring significant financial and human capital to Provention in support of our commercial launch of TZIELD (teplizumab-mzwv), more than doubling our ori...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters